Research use only, not for human consumption. Email [email protected]
← Research status explorer
Neuro / Cognitive

Semax

Current research status Human Research
Limited/regional clinical research
Preclinical
Human Research

What is it?

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) built from an ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro tripeptide, and is described as an analogue of ACTH(4-10) that lacks hormonal activity. It was developed in Russia, where the peptide literature lists it among original Russian peptide preparations (classed as a nootropic drug). Published work has examined it in ischemic stroke recovery, cerebrovascular insufficiency and optic nerve disease in small, mostly Russian-language clinical reports, and in rodent studies of brain ischemia, neurotrophin (BDNF) expression, stress and neurodegeneration models. Semax is not an established therapy outside Russia, and the evidence summarised here is preliminary.

Research overview

Semax is a synthetic ACTH(4-10) analogue developed and studied mainly in Russia, where it is registered as a nasal-spray medication for conditions including stroke recovery and cognitive support. Its human research base comes largely from regional clinical studies rather than the kind of multinational Phase 1–3 program used for FDA approval, and it does not hold FDA approval.

Mechanism of action

Semax combines the ACTH(4-7) sequence Met-Glu-His-Phe with a Pro-Gly-Pro (PGP) tail. One group describes the PGP tripeptide as a factor that helps peptide drugs resist biodegradation [PMID 36553646]. A hypothesis paper describes Semax as devoid of the hormonal (corticotropic) activity of ACTH [PMID 16996699]. The specific receptor or receptors through which Semax acts have not been established in the records reviewed.

The best-replicated proposal is modulation of neurotrophin signalling. In rats, a single intranasal application was reported to raise BDNF protein, trkB phosphorylation and BDNF/trkB mRNA in the hippocampus [PMID 16996037], and to raise BDNF protein in the basal forebrain, where specific, saturable binding sites for labelled Semax (dissociation constant about 2.4 nM) were also reported in isolated membranes [PMID 16635254]. After experimental cerebral ischemia, Semax was reported to alter transcription of several neurotrophin and Trk receptor genes in rat cortex [PMID 19633950]. The molecular identity of the binding sites is not defined in these abstracts, and whether the BDNF changes cause any functional effect is an inference.

Genome-wide and protein-level work in rat ischemia models points to anti-inflammatory and immune-related effects. In the transient middle cerebral artery occlusion model, Semax was reported to suppress inflammation-related gene expression and to preserve neurotransmission-related expression [PMID 32580520]. In a permanent-occlusion model it was reported to change expression of immune-response and vascular-system genes [PMID 24661604]. At the protein level it was reported to lower MMP-9, c-Fos and active JNK and raise active CREB in specific regions [PMID 34201112]. These are expression changes observed alongside treatment, so they show association rather than proven mechanism.

Other proposals are more tentative. Semax was compared with the melanocortin receptor agonist Melanotan II in a rat chronic-stress model, which is consistent with, but does not demonstrate, melanocortin-system involvement [PMID 39442746]. A mouse spinal cord injury study proposed the mu-opioid receptor and a USP18/FTO pathway as targets, based partly on network pharmacology and docking [PMID 40692165], and an in vitro study reported that Semax binds copper(II) and affects copper-associated amyloid-beta aggregation [PMID 35080861]. None of these has been confirmed independently in humans.

Adult human evidence

Ischemic stroke recovery: A Russian report of 110 adults after ischemic stroke (mean age about 58 years) divided patients into early and late rehabilitation groups, each with Semax-treated and untreated subgroups. The authors reported higher plasma BDNF in the Semax subgroups, faster improvement on the Barthel index and an association between early rehabilitation and better motor performance [PMID 29798983]. The abstract does not describe randomisation, blinding or a placebo, plasma BDNF is a surrogate marker, and correlations with BDNF do not show that BDNF mediated any benefit. An earlier controlled study in acute hemispheric ischemic stroke compared 30 Semax-treated patients (older adults, as indexed by PubMed) with 80 patients given conventional therapy, using clinical scales, EEG mapping and somatosensory evoked potentials; the authors reported a faster regression of general cerebral and focal, especially motor, deficits [PMID 11517472]. Randomisation and blinding are not stated in the abstract, and the study dates from 1997.

Chronic cerebrovascular disease: A comparative evaluation of 187 patients with different stages of cerebrovascular insufficiency reported clinical improvement, stabilisation and a lower risk of stroke and transient ischemic attacks, with few side effects and good tolerability, including in older patients [PMID 15792140]. The abstract does not describe the comparator, blinding or outcome definitions, so the strength of these conclusions cannot be judged from it.

Optic nerve conditions: In a 2022 study of 60 patients with vascular optic neuropathy (mean age about 66 years), Semax 0.1% by endonasal electrophoresis was one component of a combined neurostimulation programme (transcranial stimulation, oxybaric chamber and acupuncture) compared with a vitamin-only control group. The authors reported larger visual-field and retinal ganglion complex improvements in the treated group [PMID 36083821]. Because Semax was combined with several other interventions and the control group received no sham procedures, its individual contribution cannot be separated. An earlier comparative report in glaucomatous optic neuropathy with normalised eye pressure (patients indexed as middle-aged or older) described electrophysiological advantages for a neuroprotective regimen including Semax over traditional neuroprotective treatment; the English abstract gives no sample size or design detail [PMID 11569188].

Healthy volunteers: In a placebo-controlled resting-state fMRI study of 24 healthy adults (mean age about 44 years; 14 given intranasal Semax, 10 placebo), the Semax group had a larger medial-frontal subcomponent of the default mode network than controls [PMID 30225715]. A separate fMRI connectivity study in 52 healthy participants reported differences in right amygdala to right temporal cortex connectivity after Semax or Selank compared with placebo [PMID 32342318]. These are brain-imaging observations in small samples and are not evidence of clinical or cognitive benefit.

Overall, the human literature found here consists of small to moderate studies, mostly in Russian-language or regional journals, with limited methodological detail in the English abstracts. No registered trials were found on ClinicalTrials.gov, and no large randomised placebo-controlled trial was identified in this search.

Preclinical evidence

Neurotrophin expression (rat): Intranasal Semax was reported to increase BDNF protein and trkB phosphorylation, with a 3-fold rise in exon III BDNF mRNA and a 2-fold rise in trkB mRNA, in the hippocampus, alongside an increased number of conditioned avoidance reactions [PMID 16996037]. In the basal forebrain, Semax increased BDNF protein after 3 hours, and tritium-labelled Semax showed specific, reversible, calcium-dependent binding to membranes [PMID 16635254]. A real-time PCR study reported rapid, gene- and region-specific changes in Ngf and Bdnf expression in normal rat brain within 1 hour [PMID 17353092].

Cerebral ischemia models (rat): After permanent middle cerebral artery occlusion, Semax was reported to enhance transcription of Bdnf, Ngf, Nt-3 and Trk receptor genes at different time points [PMID 19633950], and to alter expression of immune-response and vascular genes [PMID 24661604]. After transient occlusion with reperfusion, RNA-seq identified 394 differentially expressed genes at 24 hours; Semax was reported to suppress inflammation-related and activate neurotransmission-related expression [PMID 32580520], with matching protein-level changes in CREB, MMP-9, c-Fos and JNK [PMID 34201112]. These studies measure molecular changes; infarct size and behaviour were not the focus of the abstracts cited.

Stress and mood models: In adult male rats under chronic unpredictable stress, daily systemic Semax and Melanotan II reversed or attenuated anhedonia, body-weight suppression, adrenal hypertrophy and a fall in hippocampal BDNF; no effect was seen in the forced swim test [PMID 39442746]. Effects were studied in males only.

Other models: In C57BL/6 female mice with spinal cord injury and in a PC12 cell neuroinflammation model, Semax was reported to improve functional recovery and reduce pyroptosis-related markers, with a proposed mu-opioid receptor/USP18 pathway [PMID 40692165]. In transgenic Alzheimer-type mice, Semax and a derivative were reported to improve behavioural test results and reduce amyloid deposits [PMID 41479572]. In artificial membrane models, Semax was reported to interfere with copper-associated amyloid-beta aggregation [PMID 35080861]. Rodent and in vitro findings frequently do not translate to humans.

Evidence limitations

  • Human data are limited to small or moderate studies, many from Russian-language or regional journals, and English abstracts often omit randomisation, blinding, placebo use and prespecified outcomes.
  • Several human outcomes are surrogate or imaging markers (plasma BDNF, EEG, fMRI) whose link to clinical benefit has not been demonstrated, and the optic nerve study tested Semax only as part of a multi-modality programme.
  • Most mechanistic evidence is rat gene or protein expression, which shows association rather than causation; the receptor target of Semax is not established, and the molecular identity of binding sites reported in rat membranes is not defined in the abstracts reviewed.
  • No studies of Semax were found on ClinicalTrials.gov, and no large, independently replicated, placebo-controlled randomised trial was identified in this search.
  • Long-term safety, optimal use and effects in different populations are not established by the sources reviewed, and the English abstracts give only brief tolerability statements.
  • An analytical study of seized preparations reported Semax and Selank sold online as lyophilised powders and nasal sprays outside regulated channels, so identity and purity of non-pharmaceutical material cannot be assumed [PMID 31667971].

Research and regulatory status

Semax is described in the peptide-drug literature as an original Russian peptide preparation classed as a nootropic drug [PMID 35456550], and a 2023 review (Russian-based authors) states in its full text that it has been used in neurological practice for many years for acute and chronic disorders including ischemic stroke and its consequences [PMID 37239313]; the specific registration record and dosage forms were not checked in a Russian drug register. A ClinicalTrials.gov search on 2026-11-20 for Semax, Semax nasal spray and ACTH(4-7)PGP returned no registered studies. A 2020 analytical paper stated that, to the authors' knowledge, Semax and Selank had not completed any clinical trials, and that both were sold online outside regulated channels [PMID 31667971].

Key studies

Adult human study

The efficacy of semax in the tretament of patients at different stages of ischemic stroke.

Gusev EI, Martynov MY, Kostenko EV, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018

Design
Clinical study with early and late rehabilitation groups, each split into Semax and no-Semax subgroups
Participants / model
Adults after ischemic stroke (mean age 58.0 ± 9.7 years; 43 men, 67 women)
Sample size
110 patients
Principal findings
Semax administration was reported to raise plasma BDNF levels, which stayed high through the study period, and to accompany faster improvement and a better final Barthel index score. Early rehabilitation was associated with higher BDNF and better motor performance.
Limitations
The abstract does not describe randomisation, blinding or placebo, and much of the reported effect is correlational. Plasma BDNF is a surrogate marker, and the study appeared in a Russian-language journal.

PubMed 29798983 DOI 10.17116/jnevro20181183261-68

Adult human study

Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study).

Gusev EI, Skvortsova VI, Miasoedov NF, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 1997

Design
Controlled clinical study comparing Semax added to conventional therapy with conventional therapy alone
Participants / model
Patients in the acute period of hemispheric ischemic stroke (indexed in PubMed as aged adults)
Sample size
30 Semax patients and 80 control patients
Principal findings
Adding Semax to combined intensive therapy was reported to have some influence on the rate of recovery of neurological function, with greater regression of general cerebral and focal, especially motor, disorders. EEG mapping and somatosensory evoked potentials were used to monitor brain function.
Limitations
The abstract does not state randomisation, blinding or a placebo, and the control group was larger than the treated group. The study is from 1997 and used a regional Russian-language journal.

PubMed 11517472

Adult human study

Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency.

Gusev EI, Skvortsova VI, Chukanova EI · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2005

Design
Comparative evaluation study in patients with cerebrovascular insufficiency
Participants / model
Adult patients with different stages of cerebrovascular insufficiency, including older patients
Sample size
187 patients
Principal findings
Semax treatment was reported to produce clinical improvement, stabilisation of disease progression and a reduced risk of stroke and transient ischemic attacks, with a low percentage of side effects and good tolerability, including in older patients.
Limitations
The abstract does not describe the comparator group, blinding or definitions of the outcomes. It was published in a Russian-language journal and reports clinical-impression outcomes only.

PubMed 15792140

Adult human study

Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis.

Dragon AK, Korchazhkina NB, Sheludchenko VM, et al. · Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury · 2022

Design
Two-group comparative study of a combined neurostimulation programme (including endonasal Semax electrophoresis) versus vitamin-only control
Participants / model
Adults with optic neuropathy of vascular origin (mean age 66.2 ± 4.1 years); 20 healthy volunteers were used for reference values
Sample size
60 patients (30 treated, 30 control)
Principal findings
The authors reported that the treated group had larger visual-field boundaries, better light sensitivity and lower global losses of the retinal ganglion complex than controls, with 'therapeutic efficacy' of 94%, 88% and 83% at 1, 12 and 24 weeks versus 30-42% in controls.
Limitations
Semax was only one part of a multi-modality programme, so its individual effect cannot be isolated, and the control group received no sham or placebo procedures. The efficacy percentages are author-defined and the abstract does not describe masking.

PubMed 36083821 DOI 10.17116/kurort20229904272

Adult human study

Effects of Semax on the Default Mode Network of the Brain.

Lebedeva IS, Panikratova YR, Sokolov OY, et al. · Bulletin of experimental biology and medicine · 2018

Design
Placebo-controlled resting-state fMRI study with scans before and 5 and 20 minutes after intranasal administration
Participants / model
Healthy volunteers (11 men and 13 women, mean age 43.9 ± 9.5 years)
Sample size
24 volunteers (14 Semax, 10 placebo)
Principal findings
A greater volume of the rostral (medial frontal cortex) subcomponent of the default mode network was reported in the Semax group than in controls.
Limitations
Small sample with a single short session and imaging outcomes only, so no cognitive or clinical effect is shown. The abstract does not state the blinding method.

PubMed 30225715 DOI 10.1007/s10517-018-4234-3

Preclinical (animal / cell)

Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.

Dolotov OV, Karpenko EA, Seredenina TS, et al. · Journal of neurochemistry · 2006

Design
In vivo intranasal administration and in vitro radioligand binding in rat brain tissue
Participants / model
Rat basal forebrain and cerebellum membranes and tissue
Sample size
not stated in the abstract
Principal findings
Tritium-labelled Semax showed time-dependent, specific, reversible, calcium-dependent binding to basal forebrain membranes (KD about 2.4 nM). Intranasal Semax was reported to raise BDNF protein in the basal forebrain after 3 hours but not in the cerebellum.
Limitations
The identity of the binding sites is not established and the study is in rats only. Increased BDNF was not linked directly to a functional outcome.

PubMed 16635254 DOI 10.1111/j.1471-4159.2006.03658.x

Preclinical (animal / cell)

Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. · Brain research · 2006

Design
Single intranasal administration with molecular and behavioural readouts in rats
Participants / model
Rat hippocampus
Sample size
not stated in the abstract
Principal findings
A single application was reported to produce up to a 1.4-fold increase in BDNF protein, a 1.6-fold increase in trkB phosphorylation, and 3-fold and 2-fold increases in exon III BDNF and trkB mRNA. The treated animals also showed more conditioned avoidance reactions.
Limitations
Findings are from rats and measure molecular markers and a learning task. The causal link between BDNF/trkB changes and cognition is a suggestion by the authors, not a demonstrated result.

PubMed 16996037 DOI 10.1016/j.brainres.2006.07.108

Preclinical (animal / cell)

Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.

Dmitrieva VG, Povarova OV, Skvortsova VI, et al. · Cellular and molecular neurobiology · 2010

Design
Permanent middle cerebral artery occlusion (pMCAO) model with mRNA analysis at three time points
Participants / model
Rat cortex (pMCAO, sham-operated and non-operated rats)
Sample size
not stated in the abstract
Principal findings
Semax was reported to enhance transcription of Bdnf, TrkC and TrkA at 3 hours, Nt-3 and Ngf at 24 hours, and Ngf at 72 hours after occlusion. The Pro-Gly-Pro tripeptide had partly overlapping but mainly nonspecific effects.
Limitations
Reports mRNA expression, not infarct size or behaviour, and mRNA changes may not correspond to protein or function. Rat model only.

PubMed 19633950 DOI 10.1007/s10571-009-9432-0

Preclinical (animal / cell)

Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats.

Filippenkov IB, Stavchansky VV, Denisova AE, et al. · Genes · 2020

Design
RNA-seq transcriptome analysis in a transient middle cerebral artery occlusion (tMCAO) model
Participants / model
Rat brain 24 hours after tMCAO, Semax compared with saline
Sample size
not stated in the abstract
Principal findings
394 differentially expressed genes were identified. Semax was reported to suppress expression of genes related to inflammatory processes and to activate expression of genes related to neurotransmission, compensating for patterns disrupted by ischemia-reperfusion.
Limitations
A single time point (24 hours) in rats, with gene-expression endpoints. The abstract does not report functional or tissue-damage outcomes.

PubMed 32580520 DOI 10.3390/genes11060681

Preclinical (animal / cell)

Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress.

Inozemtseva LS, Yatsenko KA, Glazova NY, et al. · European journal of pharmacology · 2024

Design
Chronic unpredictable stress model with daily intraperitoneal peptide injections
Participants / model
Adult male Sprague-Dawley rats; Semax and the melanocortin agonist Melanotan II were compared with saline
Sample size
not stated in the abstract
Principal findings
Both peptides were reported to reverse or attenuate stress-induced anhedonia, body-weight suppression, adrenal hypertrophy and the fall in hippocampal BDNF. No effect on immobility was detected in the forced swim test.
Limitations
Male rats only, and rodent behavioural tests are imperfect models of depression. The abstract does not establish which receptor mediates the effects.

PubMed 39442746 DOI 10.1016/j.ejphar.2024.177068

Review

Development of Peptide Biopharmaceuticals in Russia.

Deigin VI, Poluektova EA, Beniashvili AG, et al. · Pharmaceutics · 2022

Design
Narrative review of peptide drug development in the Russian Federation
Participants / model
Not applicable (literature review)
Sample size
not applicable
Principal findings
The review outlines the history and approaches to developing peptide drugs, with a focus on original Russian peptide drugs. Its full text (not just the abstract) lists Semax among original Russian peptide preparations as a nootropic drug.
Limitations
Semax is not mentioned in the abstract and is only one of many peptides covered, so the review does not evaluate the clinical evidence for Semax in depth.

PubMed 35456550 DOI 10.3390/pharmaceutics14040716

Review

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Mavrych V, Shypilova I, Bolgova O · Frontiers in aging · 2026

Design
Narrative review of nine peptides (including Semax) using PubMed, Scopus and regulatory databases through January 2026
Participants / model
Not applicable (literature review of 20 primary sources)
Sample size
20 primary sources across nine peptides
Principal findings
The review groups Semax with the neuroprotection category and concludes that non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation.
Limitations
Semax is one of nine peptides, so coverage is brief and not specific to Semax. As a narrative review it can carry selection bias.

PubMed 42021992 DOI 10.3389/fragi.2026.1790247

Last reviewed: 20 November 2026